Prospective Comparison of <sup>68</sup>Ga-FAPI versus                     <sup>18</sup>F-FDG PET/CT for Tumor Staging in Biliary Tract                     Cancers

Lan, Lianjun; Zhang, Shumao; Xu, Tingting; Liu, Huipan; Wang, Wei; Feng, Yue; Wang, Li; Chen, Yue; Qiu, Lin

doi:10.1148/radiol.213118

Cited by 29 publications

(96 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CT may depend on the higher tracer uptake in different types of ovarian malignancies and lower TBRs, which is consistent with previous studies [10,18,19]. However, 68 Ga-FAPI PET/CT was not a more tumor-specific imaging modality than 18 F-FDG PET/CT for detecting node metastases [20][21][22]. For example, one patient exhibited false-positive on both imaging modalities because of lymphadenitis.…”

Section: Discussionsupporting

confidence: 86%

Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies

Zheng

Liu

Feng

et al. 2022

Nuclear Medicine Communications

Self Cite

View full text Add to dashboard Cite

Background Currently, fluorine-18-fluorodeoxyglucose ( 18 F-FDG) is the most frequently used diagnostical radiotracer for PET/computed tomography (PET/CT) in ovarian malignancies. However, 18 F-FDG has some limitations. The fibroblast activation protein inhibitor (FAPI) previously demonstrated highly promising results in studies on various tumor entities and 68 Ga-labeled FAPI presents a promising alternative to 18 F-FDG. This study aimed to compare the performance of 68 Ga-FAPI and 18 F-FDG PET/CT for imaging of ovarian malignancies.Methods A total of 27 patients were included in this retrospective study conducted at the Affiliated Hospital of Southwest Medical University between June 2020 and February 2022. The 18 F-FDG and 68 Ga-FAPI uptakes of tumors, lymph nodes, and distant metastases were quantified using the maximum standardized uptake values, and the tumor-to-background ratios were also evaluated and calculated by using the Wilcoxon signedrank test. ResultsTwenty-one patients with suspected (n = 11) and previously treated ovarian malignancies (n = 10) were in statistical analysis finally. For detecting tumors, 68 Ga-FAPI PET/CT was more sensitive than 18 F-FDG PET/ CT [14 of 14 (100%) vs. 11 of 14 (78%)], lymph node metastases [75 of 75 (100%) vs. 60 of 75 (80%)] and superior to 18 F-FDG PET/CT in terms of the peritoneal and pleural metastases [9 of 9 (100%) vs. 5 of 9 (56%)]. For four of the newly diagnosed patients (n = 11), 68 Ga-FAPI PET/CT upstaged the clinical stage compared to 18 F-FDG PET/CT. Conclusion 68 Ga-FAPI PET/CT has superior potential in the detection of ovarian cancers, especially in peritoneal carcinomatosis. 68 Ga-FAPI PET/CT may be a promising supplement for staging and follow-up of ovarian malignancies.

show abstract

Section: Discussionsupporting

confidence: 86%

Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies

Zheng

Liu

Feng

et al. 2022

Nuclear Medicine Communications

Self Cite

View full text Add to dashboard Cite

show abstract

“…Postoperative follow-up and recurrence detection for gastrointestinal tumors are helpful for patient management. 68 Ga-FAPI is a very promising tumor imaging agent, which represents a promising alternative to 18 F-FDG 13 . In this study, 68 Ga-FAPI-04 PET/CT demonstrated a higher detection efficacy for tumor recurrence (6 of 6 [100%] vs 4 of 6 [67%]), nodal metastases (92 of 92 [100%] vs 31 of 92 [34%]), and distant metastases (28 of 30 [93%] vs 20 of 30 [67%]) in participants with gastric, duodenal, and colorectal cancers compared with the detection efficacy of 18 F-FDG PET/CT.…”

Section: Discussionmentioning

confidence: 99%

Comparison of 18F-FDG and 68Ga-FAPI-04 Uptake in Postoperative Re-evaluation of Gastric, Duodenal, and Colorectal Cancers

et al. 2023

Self Cite

View full text Add to dashboard Cite

PurposeTo compare the potential efficacy of 68Ga-FAPI-04 PET/CT with that of 18F-FDG PET/CT for detecting tumor recurrence and nodal and distant metastases in gastric, duodenal, and colorectal cancers.MethodsThis single-center retrospective clinical study was performed at the Affiliated Hospital of Southwest Medical University between January 2020 and June 2022. Participants with gastric, duodenal, and colorectal cancers after curative resection underwent both 68Ga-FAPI-04 and 18F-FDG PET/CT. Histopathologic examination, morphologic imaging, and/or follow-up imaging served as the reference standards. The SUVmax of the tumor recurrence and nodal and distant metastases between 18F-FDG and 68Ga-FAPI-04 PET/CT were compared using the paired-sample t test.ResultsForty-one participants with gastric, duodenal, and colorectal cancers were enrolled in the study (median age, 51 years; range, 19–75 years). The sensitivity of 68Ga-FAPI-04 PET/CT was higher than that of 18F-FDG PET/CT for detecting tumor recurrence (6 of 6 [100%] vs 4 of 6 [67%]), nodal metastases (92 of 92 [100%] vs 31 of 92 [34%]), and distant metastases (28 of 30 [93%] vs 20 of 30 [67%]).Conclusion68Ga-FAPI-04 PET/CT for tumor re-evaluation showed potential for more accurate performance of gastric, duodenal, and colorectal cancers, thereby improving treatment decision-making.

show abstract

“…However, there was no need to make any preparations in order to take the 68 Ga-FAPI-04 PET/CT test. The doses of 68 Ga-FAPI-04 and 18 F-FDG that were administered via intravenous injection were 3.7 and 1.85 MBq/kg, respectively ( 19 , 20 ). Following a tracer injection, participants got a PET/CT scan (uMI780, United Imaging Healthcare) 40–60 mins later.…”

Section: Methodsmentioning

confidence: 99%

Prospective comparison of 68Ga-FAPI-04 and 18F-FDG PET/CT for tumor staging in nasopharyngeal carcinoma

Ding

Liu²,

Qiu³

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

PurposeTo explore the difference in the effectiveness of gallium-68 fibroblast activation protein inhibitor (68Ga-FAPI-04) PET/CT and fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT for the initial staging of patients with nasopharyngeal carcinoma (NPC).MethodsThe Affiliated Hospital of Southwest Medical University hosted this single-center prospective investigation (Clinical Trials registration No.ChiCTR2100044131) between March 2020 and September 2021. Within a week, all subjects underwent MR scans, 68Ga-FAPI-04 PET/CT, and 18F-FDG PET/CT in order. The effectiveness of medical staging employing 68Ga-FAPI-04 and 18F-FDG PET/CT was compared.ResultsTwenty-eight patients with primary NPC were evaluated (mean age53 ± 11 years). 68Ga-FAPI-04 PET/CT indicated an elevated recognition rate for diagnosing primary tumors (28/28 [100%] vs. 27/28 [96%]) and lymph node metastases (263/285 [92%] vs. 228/285 [80%]), but a lower detection rate for distant metastases (5/7 [71%] vs. 7/7 [100%]) compared with 18F-FDG PET/CT. A significant association between the maximum standard uptake value (SUVmax) of 18F-FDG PET and 68Ga-FAPI-04 PET was found in the primary cancers (r = 0.691, p < 0.001). In comparison to 18F-FDG PET/CT, 68Ga-FAPI-04 PET/CT upstaged the T stage in five patients while downstaging the N stage in seven patients. 68Ga-FAPI-04 PET/CT corrected the overall staging of five patients on18F-FDG PET/CT.Conclusion68Ga-FAPI-04 PET/CT is preferable to 18F-FDG PET/CT for NPC staging in terms of the detection efficiency for primary tumors and lymph node metastasis. This is especially true when evaluating the primary cancer and any spread to contiguous tissues. It is possible to improve the staging assessment of NPC by using 68Ga-FAPI-04 PET/CT in conjunction with 18F-FDG PET/CT.

show abstract

Prospective Comparison of ⁶⁸Ga-FAPI versus ¹⁸F-FDG PET/CT for Tumor Staging in Biliary Tract Cancers

Cited by 29 publications

References 28 publications

Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies

Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies

Comparison of 18F-FDG and 68Ga-FAPI-04 Uptake in Postoperative Re-evaluation of Gastric, Duodenal, and Colorectal Cancers

Prospective comparison of 68Ga-FAPI-04 and 18F-FDG PET/CT for tumor staging in nasopharyngeal carcinoma

Contact Info

Product

Resources

About

Prospective Comparison of 68Ga-FAPI versus 18F-FDG PET/CT for Tumor Staging in Biliary Tract Cancers

Cited by 29 publications

References 28 publications

Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies

Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies

Comparison of 18F-FDG and 68Ga-FAPI-04 Uptake in Postoperative Re-evaluation of Gastric, Duodenal, and Colorectal Cancers

Prospective comparison of 68Ga-FAPI-04 and 18F-FDG PET/CT for tumor staging in nasopharyngeal carcinoma

Contact Info

Product

Resources

About

Prospective Comparison of ⁶⁸Ga-FAPI versus ¹⁸F-FDG PET/CT for Tumor Staging in Biliary Tract Cancers